Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-02-06

Clinical Trial Update: Sargramostim Use in COVID-19 to Recover Patient Health [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sargramostim for recovery in COVID-19 patients has completed with results posted in early 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • sargramostim (sargramostim)

Snippet

Sponsor: Partner Therapeutics, Inc. | Conditions: Covid19, SARS-CoV Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-02-06